High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma To the Editor: High neutrophil-to-lymphocyte ratio (NLR) before starting cytotoxic T-lymphocytee associated antigen 4 antibody ipilimumab was previously found associated with improved overall survival (OS) in patients with metastatic melanoma. 1, 2 We examined whether high NLR is an independent risk factor for poor OS in patients receiving programmed cell death 1 (PD1) antibodies nivolumab or pembrolizumab, accounting for the main risk factors of disease progression and corticosteroids intake (which can increase NLR) in the multivariable analysis. We carried out a retrospective, multicenter study. The inclusion criteria were 1) initiating monotherapy with anti-PD1 immunotherapy for stage IV or unresectable stage III melanoma during July 1, 2014-November 30, 2016, and 2) a pretherapeutic blood count and lactate dehydrogenase (LDH) activity, performance status, American Joint Committee for Cancer (AJCC) stage (7th edition), and brain imaging by computed tomography or magnetic resonance imaging performed within 2 months before starting anti-PD1.
We included 101 patients (Table I) . Anti-PD1 therapy achieved disease stabilization in 5 of 101 patients (5.0%), a partial response in 9 (8.9%), and a complete response in 21 (20.8%). During treatment, metastatic melanoma progressed in 68 patients (67.3%); 49 (46.5%) died from melanoma. The median OS was 10 (interquartile range [IQR] 5.8-17.6) months and median progression-free survival 5.7 (IQR 2.9-12.6) months. These data did not differ for the 2 drugs used, nivolumab or pembrolizumab (Supplemental Fig 1; available at http://www.jaad.org). Short OS was associated with high NLR (continuous NLR or dichotomized NLR $5), absolute neutrophil count at week 1 of $7.5 3 10 9 /L, (Supplemental Fig 2; available at http://www.jaad.org), LDH activity $2 upper limit of normal, symptomatic brain metastases, corticosteroid use, and performance status $1) (Table II) . On multivariable analysis, short OS remained associated with elevated LDH activity $2 N, symptomatic brain metastases, NLR $5, and performance status $1.
In this retrospective study, high NLR before starting PD1 antibody therapy with nivolumab or pembrolizumab was an independent prognostic factor associated with poor survival on multivariable analysis when accounting for corticosteroid use (which might also increase NLR) and other prognostic factors, such as high LDH level, performance status $1, symptomatic brain metastasis, and AJCC stage $M1b. In patients receiving nivolumab for lung cancer, pretherapeutic NLR $5 was associated with short OS (hazard ratio 2.07, 95% confidence interval 1.3-3.3). 3 This study did not consider corticosteroid therapy in the analysis.
Inflammation associated with cancer is a determining factor in disease progression and survival. Neutrophils and other cells, such as macrophages, secrete tumor growth factors and angiogenic factors, which contribute to stimulating the tumor microenvironment. 4 Lymphocytes play a key role in the antitumor immune response 5 and secrete antitumor cytokines, which regulate tumor proliferation and angiogenesis. The NLR combines these 2 features, neutrophilia and lymphopenia, performing better than absolute number of neutrophils and lymphocytes considered separately.
The limitations of our study are the relatively small size of our cohort and its retrospective design. However, this study included a consecutive series of all the patients in 3 hospitals in real life, and we included patients receiving either of the 2 available anti-PD1 agents. Consideration of oral corticosteroids is a highlight of our study. Indeed, as compared with most studies, in the multivariable analysis, we accounted for the main confounding factor that can modify the NLR, systemic corticosteroids treatment. We did not account for other factors of elevated neutrophil count, such as smoking.
High NLR is an independent prognostic factor indicating worse outcome with melanoma. We 
Dupilumab for hand eczema
To the Editor: Hand eczema is common, affecting about 10% of the general population over a 1-year period, with a poor long-term prognosis regardless of the etiology. 1 In severe cases it has a significant impact on quality of life, with major effects on social interactions, occupational success, and activities of daily living. 2 There are multiple etiologies and clinical patterns, but there is no consistent correlation between the etiology and the clinical pattern. Various classification schemes have existed over the years, but none has been generally accepted. In many patients it is not possible to identify the etiology, even after extensive investigation and long-term follow-up. Although many mild cases respond well to lifestyle changes, moisturizers, and intermittent topical steroids, there is no consistently effective topical or systemic therapy for severe disease.
The charts of all patients treated with dupilumab at a single center were reviewed to identify those with dermatitis involving primarily the hands. Three patients treated with dupilumab for severe, chronic, recalcitrant hand eczema were identified. Information on personal and family history of atopy, clinical aspects of the hand eczema, presence of dermatitis in other locations, history of response to prior therapies, and response to dupilumab treatment was collected. All 3 patients had substantial responses to dupilumab, ranging from 80% improvement to complete clearance.
Patient characteristics, efficacy of prior topical and systemic steroids, and response to dupilumab are presented in Table I . All patients were treated with the standard US Food and Drug Administratione approved dosing of 600 mg subcutaneously on day 1 followed by 300 mg subcutaneously every 14 days. It should be noted that before dupilumab therapy, all 3 patients underwent comprehensive patch testing and no relevant allergens were detected.
Dupilumab is the first US Food and Drug Administrationeapproved therapy for moderate-tosevere atopic dermatitis. Its efficacy, both as monotherapy and in conjunction with corticosteroids, has been demonstrated in multiple double-blind, randomized, clinical trials. 3 In all the reported trials inclusion criteria indicated that atopic dermatitis must affect greater than 10% of the body surface area. 3 Because the palm including the fingers comprises 1% of the body surface area, the studies specifically excluded patients with atopic dermatitis limited to the hands.
